Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

pany, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL184, the future conduct of the phase 1/2 trial of XL184 and the expected timing of the initiation of a pivotal trial of XL184. Words such as "expected," "will," "planning", "suggest" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the lengthy, costly and uncertain process of clinical testing of XL184 and the potential failure of XL184 to demonstrate safety and efficacy in clinical testing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' quarterly report on Form 10-Q for the quarter ended September 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... March 26, 2015 According to ... Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional ... Cancer, Bone Metastasis) - Global Forecasts to 2019", published ... reach around $462.0 Million growing at a CAGR of ... tables and 57 figures spread through 195 pages and ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... 2011 Cardica, Inc. (Nasdaq: CRDC ) today ... 30, 2011. Cardica,s management will host a conference call at ... and provide an update on the company,s business. ... Dr. Swanstrom, a world-renowned key opinion leader in laparoscopic surgery, ...
... ($ in millions, except per share data, unaudited)ItemQ3 2011Q3 ... Net Product Revenue , $112.9 , 16.9% increaseNaglazyme Net ... Product Revenue* , $23.0 , $16.5Kuvan Net Product ... , $3.5 , 59.1% increaseGAAP Net Income (Loss) , ...
Cached Medicine Technology:Cardica Announces Fiscal 2012 First Quarter Financial Results 2Cardica Announces Fiscal 2012 First Quarter Financial Results 3Cardica Announces Fiscal 2012 First Quarter Financial Results 4Cardica Announces Fiscal 2012 First Quarter Financial Results 5Cardica Announces Fiscal 2012 First Quarter Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 2BioMarin Announces Third Quarter 2011 Financial Results 3BioMarin Announces Third Quarter 2011 Financial Results 4BioMarin Announces Third Quarter 2011 Financial Results 5BioMarin Announces Third Quarter 2011 Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 7BioMarin Announces Third Quarter 2011 Financial Results 8BioMarin Announces Third Quarter 2011 Financial Results 9BioMarin Announces Third Quarter 2011 Financial Results 10BioMarin Announces Third Quarter 2011 Financial Results 11BioMarin Announces Third Quarter 2011 Financial Results 12BioMarin Announces Third Quarter 2011 Financial Results 13
(Date:3/27/2015)... (PRWEB) March 27, 2015 The federal ... that allege the statin medication increases the risk that ... Pfizer Inc.’s Motion to Dismiss four individual cases that ... Case Management Order issued in the U.S. District Court, ... determined that the dismissals were warranted because the plaintiffs ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... New York, NY (PRWEB) March 27, 2015 Ticket ... Live in Concert in 2015. After a phenomenal and ... hit show "Nashville" will be going out on tour again in ... The tour gets underway on April 29th in New York ... Phoenix, AZ at the Comerica Theatre on May 10th. , Fans ...
(Date:3/27/2015)... While deep learning was the topic of ... (GTC) , the CEO of one start-up spoke passionately about ... lifespan well beyond the generally-agreed ceiling of 120 years. , ... one of 12 companies recognized as the hottest GPU-powered startups ... GTC Emerging Companies Summit have business models focused ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... ORLANDO, Fla. Results of a study presented at the ... credence to the idea that improving quality of life affects ... cancer. Researchers know that telomeres shorten and deteriorate with ... length. "We are trying to understand the interconnections between ...
... , FRIDAY, April 1 (HealthDay News) -- At-home pregnancy tests ... on the way and if it is time to call ... offer tantalizing clues about future health risks -- are still ... results may puzzle or even panic consumers who don,t seek ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... Germany, Saturday 02 April 2011: Exciting new data presented ... quadruple therapy in chronic hepatitis C (HCV) patients suppressed ... 100% rate of sustained virological response - undetectable HCV ... the quadruple therapy study, HCV patients were given four ...
... Fla. The combination of two compounds that inhibit ... showing promise in an ongoing Phase I trial, according ... 2011, held here April 2-6. The research, ... GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. ...
... (HealthDay News) -- Updated guidelines to keep children happy, safe ... week by the American Academy of Pediatrics. When deciding ... and overall well-being, to ensure their child can effectively participate ... and mentally prepare their child for camp, and team with ...
Cached Medicine News:Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 3Health News:Antidepressants linked to thicker arteries 2Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: